Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma
Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma
复制标题
DOI：
10.1634/theoncologist.2012-0388
复制
发表时间：
2013-04-01
期刊：
影响因子：
5.8
通讯作者：
O'Neil, Bert
中科院分区：
文献类型：
--
作者：
Sampat, Keeran R.;O'Neil, Bert
肝细胞癌（HCC）是全世界死亡的重要原因。 HCC 是一种高度血管化的肿瘤，促血管生成细胞因子，如血管内皮生长因子 (VEGF)、血小板源性生长因子 (PDGF) 和成纤维细胞生长因子可能在这种疾病中发挥至关重要的作用。索拉非尼是一种阻断 VEGF 和 PDGF 信号传导的多激酶抑制剂，是第一个被证明可以改善晚期 HCC 患者生存的全身疗法。其他几种针对 VEGF 的药物正在开发中。由于预计抗 VEGF 疗法最终会产生耐药性，因此正在研究也针对替代的促血管生成途径的药物。回顾了最近的临床和临床前数据以及正在进行的研究。肿瘤学家 2013 年；18:430-438
Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor may play crucial roles in this disease. Sorafenib, a multikinase inhibitor that blocks VEGF and PDGF signaling, was the first systemic therapy to demonstrate improved survival in patients with advanced HCC. Several other drugs targeting VEGF are in development. Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed. The Oncologist 2013;18:430-438